Understanding HAE

Dariela, a real HAE patient, helps prevent her attacks with CINRYZE.

Prophylactic Therapy for HAE

Routine prophylaxis may help patients prevent and reduce the frequency and severity of hereditary angioedema (HAE) attacks.1,2

Routine prophylaxis can help patients take control

When determining whether prophylactic treatment is appropriate for an HAE patient, frequency of attacks is not the only criterion.2 Disease severity can be different for each patient, so treatment plans should be personalized based on individual needs.1-3 When evaluating your patients, several important factors should be included in consideration of prophylactic therapy, and include the following:

  • Frequency of attacks1,3
  • Severity of attacks1,3
  • Past laryngeal attacks4
  • Patient experience and preference1

US and international guidelines support routine prophylaxis as an important option2,5

According to guidelines put forth by HAE treatment experts, routine prophylactic therapy is appropriate for patients for whom on-demand acute treatment is inadequate* to minimize the suffering related to the disease.2

Treatment guidelines also reinforce that the decision to use prophylactic therapy cannot be made on rigid criteria but should reflect the needs of the individual patient1-3 and that home plasma-derived C1-INH self-infusion programs should be offered to patients.5 Additionally, guidelines recommend that patients should be evaluated for long-term prophylactic treatment at every visit and that adaptation of a treatment plan may be required to ensure that patient needs are being met.3

* "Inadequate" was tentatively defined as greater than 12 severe attacks per year, or more than 24 days of swelling (even if mild) per year.

Collaborative treatment decisions between physicians and patients are critical1

Patient input is important in determining overall disease burden. When talking with your patients, consider discussing:

  • Therapy administration options1
  • Potential risks and physical benefits of prophylaxis1

You may also want to recommend an on-demand treatment option available for HAE attacks. Click here to learn more about one option to treat HAE attacks in adults.

You might also be interested in:

References

  1. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
  2. Cicardi M, Bork K, Cabellero T, et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147-157.
  3. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update [published online ahead of print January 10, 2018]. Allergy. doi:10.1111/all.13384.
  4. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30–S40.
  5. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.

Definition: